Dissolution of capsule with cross-linking
In this article, Jigar Shah, Senior Group Leader in Analytical Development at Baroque Pharmaceuticals, explores the intricacies of capsule dissolution testing.
List view / Grid view
In this article, Jigar Shah, Senior Group Leader in Analytical Development at Baroque Pharmaceuticals, explores the intricacies of capsule dissolution testing.
The recently updated ICH Q2(R2) guidance marks a significant milestone in analytical procedure validation. Dave Elder explains why.
In this article, Dave Elder delves deeper into some ongoing developments in topic areas highlighted in European Pharmaceutical Review (EPR) during 2023.
This ebook explores the potential of nanoparticle formulations for drug delivery, as well techniques to predict in vivo bioavailability of these dosage forms.
Study finds Broadband Acoustic Resonance Dissolution Spectroscopy (BARDS) to be a potentially more time-efficient and cost-effective method for solid dose stability testing.
Researchers show that combining morphologically-directed Raman spectroscopy (MDRS) with dissolution analysis allows for particle size analysis in fully formulated nasal suspension sprays.
In this podcast, Lonza’s Dr Deanna Mudie explains the importance of bioavailability, how to achieve desired bioavailability and top tips for how to select the correct dissolution media for your testing needs.
A batch of Nitrofurantoin and all unexpired stock of Desmopressin nasal spray are being recalled in the UK, the MHRA has announced.
The company announced the voluntary recall is due to low, out of specification dissolution test results in specific batches of its tetracycline products.
The Medicines and Healthcare products Regulatory Agency has issed two alerts for medicine recalls in the UK due to out of specification dissolution results and an error in decommissioning.
European Pharmaceutical Review attended a JPAG event, exploring the plethora of uses for in silico techniques in the pharmaceutical industry.
ICH M9 biopharmaceutics classification system-based biowaivers1 is currently at step 2b and feedback from interested parties is being evaluated.2 This guideline should reach the implementation stage (step 4) during 2020. However, industry still has concerns relating to several key areas of the guidance. Here, Dave Elder summarises these ICH M9…
Setting specifications for new oral products can be challenging. Too lenient, and there is a risk of passing batches of inadequate quality; too stringent, and there is a risk of rejecting acceptable batches.
Provides Drug Manufacturers with Extensive Test Results for Tubing Comparison...
Historically, dissolution testing has been used primarily as a quality control (QC) test for solid oral drug products1. Indeed, it is the only QC test which provides a measure of the quantitative release rate of the drug from the pharmaceutical product. More recently, the test has been proposed in lieu…